Immunocore Holdings plc
Immunocore Holdings plc (IMCR): 16 pipeline candidates · 1 upcoming catalyst · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
N/A
Lead: Phase 1/Phase 2
16 candidates
1 upcoming, next in ~485d
0 buys · 4 sells (180d)
A transparent, data-derived signal for Immunocore Holdings plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.5B
Cash
$452.7M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (16 candidates)
| Drug | Phase |
|---|---|
| brenetafusp | Phase 1 |
| Brenetafusp and chemotherapy | Phase 1 |
| Brenetafusp and kinase inhibitors | Phase 1 |
| Brenetafusp and monoclonal antibodies and chemotherapy | Phase 1 |
| Brenetafusp and tebentafusp | Phase 1 |
| IMC-I109V | Phase 1 |
| IMC-M113V | Phase 1/Phase 2 |
| imc-p115c | Phase 1 |
| IMC-P115C (PRAME-HLE-A02) | Phase 1 |
| imc-r117c | Phase 1/Phase 2 |
Showing 10 of 16 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
140
Total value held
$1.35B
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 4,869,798 | $146.8M |
| fmr llc | 4,829,154 | $145.6M |
| wellington management group llp | 4,706,168 | $141.9M |
| primecap management co/ca/ | 3,693,241 | $111.4M |
| tang capital management llc | 2,649,368 | $79.9M |
| caption management, llc | 1,934,286 | $58.3M |
| deep track capital, lp | 1,931,884 | $58.2M |
| bvf inc/il | 1,294,463 | $39.0M |
| millennium management llc | 1,237,403 | $37.3M |
| janus henderson group plc | 1,189,424 | $35.8M |
Showing top 10 of 140 institutional holders of Immunocore Holdings plc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Immunocore Holdings plc's pipeline?
Immunocore Holdings plc (IMCR) has 16 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Immunocore Holdings plc's lead drug candidate?
Immunocore Holdings plc's most advanced tracked candidate is brenetafusp (Phase 1) for Advanced Melanoma; Select Advanced Solid Tumors.
What is Immunocore Holdings plc's next catalyst?
Immunocore Holdings plc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-" — expected October 16, 2027.
What is Immunocore Holdings plc's market capitalization?
Immunocore Holdings plc's market capitalization is approximately $1.5B.
Who is the CEO of Immunocore Holdings plc?
Dr. Bahija Jallal Ph.D. is the chief executive officer of Immunocore Holdings plc (IMCR).
Get the full picture on Immunocore Holdings plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.